论文部分内容阅读
本组应用阿霉素苯乙烯微囊肝动脉栓塞治疗晚期肝癌14例。药动学监测示血液浓度低,无明显高峰浓度,半衰期长(t1/2=4.20±2.90天)。病人症状均有改善,42.8％病人肿块缩小。生存期延长,生存质量提高。主要不良反应为轻、中度栓塞后综合征,无严重并发症。笔者讨论了阿霉素微囊栓塞后的体内药物动态行为、临床应用方法和病例选择等问题。
In this group, doxorubicin styrene microcapsules were used for hepatic artery embolization to treat 14 cases of advanced liver cancer. Pharmacokinetic monitoring showed low blood concentrations, no significant peak concentrations, and long half-life (t1/2 = 4.20 ± 2.90 days). The patient’s symptoms improved, and 42.8% of patients had a shrinking mass. The survival period is extended and the quality of life is improved. The main adverse reactions were mild to moderate postembolization syndromes and no serious complications. The authors discussed the in vivo dynamic behavior, clinical application and case selection of doxorubicin microcapsule embolization.